One of the strengths of our WM scoring system is that it relies on antigen markers that are routinely used and widely available in haematology laboratories performing MFC analysis for B‐cell lymphomas (CD19, CD79b, CD22, FMC7 and CD27) and myeloid neoplasms (CD13). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.